Skip to main content

OSE Pharma SA (OSE.PA) Stock Price and Company Information, 2024

OSE Pharma SA

OSE.PA

Exchange: PA
Currency Euro
ISIN: FR0012127173
Primary Ticker: OSE.PA
Fiscal Year End: December
International Domestic: International
Sector: Healthcare
Industry: Biotechnology
Gic Sector: Health Care
Gic Group: Pharmaceuticals, Biotechnology & Life Sciences
Gic Industry: Biotechnology
Gic Sub Industry: Biotechnology
Description: OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against Chem R23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and Bi CKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation Fo RT, and Nantes University Hospital; and Boehringer Ingelheim, Mab Silico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.
Address: 22, boulevard Benoni Goulin, Nantes, France, 44200
Website: https://www.ose-immuno.com
Full Time Employees: 52
Updated On: 2024-11-04

Highlights

Market Capitalization: 234150256
Market Capitalization Mln: 234.15
EBITDA: 52956000
PE Ratio: 6.20
Wall Street Target Price: 11.3
Book Value: 3.74
Earnings Share: 1.73
EPS Estimate Current Year: 2.27
EPS Estimate Next Year: 2.05
Most Recent Quarter: 2024-06-30
Profit Margin: 0.55
Operating Margin TTM: 0.76
Return On Assets TTM: 0.30
Return On Equity TTM: 0.88
Revenue TTM: 83442000
Revenue Per Share TTM: 3.94
Quarterly Revenue Growth YOY: 59.80
Gross Profit TTM: 18302000
Diluted Eps TTM: 1.73
Quarterly Earnings Growth YOY: -0.95

Valuation

Trailing PE: 6.20
Forward PE: 4.38
Price Sales TTM: 2.80
Price Book MRQ: 2.74
Enterprise Value: 191369233
Enterprise Value Revenue: 2.73
Enterprise Value Ebitda: 3.36

Technicals

Beta: 0.90
52 Week High: 11.58
52 Week Low: 3.11
50 Day MA: 8.54
200 Day MA: 6.53

Earnings

Report Date: 2025-03-25
Date: 2024-12-31
Before After Market: After Market
Currency: EUR
Report Date: 2023-04-27
Date: 2023-03-31
Before After Market: After Market
Currency: EUR
Eps Actual: -0.85
Report Date: 2022-09-22
Date: 2022-06-30
Before After Market: After Market
Currency: EUR
Eps Actual: -0.11
Report Date: 2022-03-30
Date: 2021-12-31
Before After Market: After Market
Currency: EUR
Eps Actual: -0.93
Eps Difference: -0.93
Report Date: 2021-08-26
Date: 2021-06-30
Before After Market: After Market
Currency: EUR
Eps Actual: -0.64
Eps Difference: -0.64
Report Date: 2021-03-29
Date: 2020-12-31
Before After Market: After Market
Currency: EUR
Eps Actual: -0.84
Eps Difference: -0.84
Report Date: 2020-09-17
Date: 2020-06-30
Before After Market: After Market
Currency: EUR
Eps Actual: -0.21
Eps Difference: -0.21
Report Date: 2020-03-27
Date: 2019-12-31
Before After Market: Before Market
Currency: EUR
Eps Actual: -0.31
Eps Difference: -0.31
Report Date: 2019-09-05
Date: 2019-06-30
Before After Market: After Market
Currency: EUR
Eps Actual: 0.03
Eps Difference: 0.03
Report Date: 2019-03-28
Date: 2018-12-31
Before After Market: After Market
Currency: EUR
Eps Actual: 0.35
Eps Difference: 0.35
Report Date: 2018-09-06
Date: 2018-06-30
Before After Market: After Market
Currency: EUR
Eps Actual: 0.57
Eps Difference: 0.57
Report Date: 2018-04-27
Date: 2018-03-31
Currency: EUR
Eps Actual: -0.29
Eps Difference: -0.29
Report Date: 2017-09-07
Date: 2017-06-30
Before After Market: After Market
Currency: EUR
Eps Actual: -0.44
Eps Difference: -0.44
Report Date: 2017-04-28
Date: 2017-03-31
Currency: EUR
Eps Actual: -0.27
Eps Difference: -0.27
Report Date: 2016-09-09
Date: 2016-06-30
Currency: EUR
Eps Actual: 2.1
Eps Difference: 2.1
Report Date: 2016-03-21
Date: 2015-12-31
Before After Market: After Market
Currency: EUR
Eps Actual: -0.26
Eps Difference: -0.26
Date: 2025-12-31
Period: +1y
Growth: -0.09
Earnings Estimate Avg: 2.05
Earnings Estimate Low: -0.22
Earnings Estimate High: 3.13
Earnings Estimate Year Ago Eps: 2.27
Earnings Estimate Number Of Analysts: 4.00
Earnings Estimate Growth: -0.09
Revenue Estimate Avg: 63750000.00
Revenue Estimate Low: 31000000.00
Revenue Estimate High: 82720000.00
Revenue Estimate Number Of Analysts: 4.00
Revenue Estimate Growth: -0.18
Eps Trend Current: 2.05
Eps Trend7days Ago: 2.05
Eps Trend30days Ago: 2.73
Eps Trend60days Ago: 2.48
Eps Trend90days Ago: 2.48
Date: 2024-12-31
Growth: 2.92
Earnings Estimate Avg: 2.27
Earnings Estimate Low: 0.70
Earnings Estimate High: 3.48
Earnings Estimate Year Ago Eps: -1.18
Earnings Estimate Number Of Analysts: 4.00
Earnings Estimate Growth: 2.92
Revenue Estimate Avg: 77820000.00
Revenue Estimate Low: 56600000.00
Revenue Estimate High: 103690000.00
Revenue Estimate Number Of Analysts: 4.00
Revenue Estimate Growth: 33.94
Eps Trend Current: 2.27
Eps Trend7days Ago: 2.27
Eps Trend30days Ago: 0.90
Eps Trend60days Ago: 0.60
Eps Trend90days Ago: 0.60
Eps Revisions Up Last30days: 1.00
Date: 2024-09-30
Period: +1q
Date: 2024-06-30
Date: 2024-03-31
Period: +1q
Date: 2023-12-31
Growth: -0.26
Earnings Estimate Avg: -1.21
Earnings Estimate Low: -2.00
Earnings Estimate High: -0.28
Earnings Estimate Year Ago Eps: -0.96
Earnings Estimate Number Of Analysts: 3.00
Earnings Estimate Growth: -0.26
Revenue Estimate Avg: 18500000.00
Revenue Estimate High: 65000000.00
Revenue Estimate Number Of Analysts: 4.00
Revenue Estimate Growth: 0.01
Eps Trend Current: -1.21
Eps Trend7days Ago: -1.21
Eps Trend30days Ago: -1.21
Eps Trend60days Ago: -1.21
Eps Trend90days Ago: -1.21
Date: 2023-09-30
Date: 2023-06-30
Date: 2022-12-31
Growth: -0.18
Earnings Estimate Avg: -1.10
Earnings Estimate Low: -1.50
Earnings Estimate High: -0.70
Earnings Estimate Year Ago Eps: -0.93
Earnings Estimate Number Of Analysts: 4.00
Earnings Estimate Growth: -0.18
Revenue Estimate Avg: 17230000.00
Revenue Estimate Low: 15000000.00
Revenue Estimate High: 21000000.00
Revenue Estimate Number Of Analysts: 5.00
Revenue Estimate Growth: -0.34
Eps Trend Current: -1.10
Eps Trend7days Ago: -1.10
Eps Trend30days Ago: -1.10
Eps Trend60days Ago: -1.10
Eps Trend90days Ago: -1.10
Date: 2022-09-30
Date: 2022-03-31
Period: +1q
Date: 2021-12-31
Revenue Estimate Avg: 16050000.00
Revenue Estimate Low: 5000000.00
Revenue Estimate High: 25000000.00
Revenue Estimate Number Of Analysts: 4.00
Revenue Estimate Growth: -0.39
Date: 2019-12-31
Period: +1y
Revenue Estimate Avg: 20750000.00
Revenue Estimate High: 35000000.00
Revenue Estimate Number Of Analysts: 4.00
Revenue Estimate Growth: 0.10
Eps Trend7days Ago: -0.28
Eps Trend30days Ago: -0.28
Eps Trend60days Ago: -0.28
Eps Trend90days Ago: -0.28
Eps Revisions Up Last30days: 1.00
Date: 2019-06-30
Period: +1q
Revenue Estimate Avg: 18800000.00
Revenue Estimate Low: 15000000.00
Revenue Estimate High: 24610000.00
Revenue Estimate Number Of Analysts: 4.00
Revenue Estimate Growth: 1.81
Date: 2019-03-31
Revenue Estimate Avg: 18800000.00
Revenue Estimate Low: 15000000.00
Revenue Estimate High: 24610000.00
Revenue Estimate Number Of Analysts: 4.00
Revenue Estimate Growth: 1.81
Date: 2018-12-31
Revenue Estimate Avg: 18800000.00
Revenue Estimate Low: 15000000.00
Revenue Estimate High: 24610000.00
Revenue Estimate Number Of Analysts: 4.00
Revenue Estimate Growth: 1.81
Eps Trend7days Ago: 0.18
Eps Trend30days Ago: 0.18
Eps Trend60days Ago: 0.18
Eps Trend90days Ago: 0.18
Eps Revisions Up Last30days: 1.00
Date: 2023-03-31
Eps Actual: -0.9
Date: 2021-12-31
Eps Actual: -1.5
Date: 2020-12-31
Eps Actual: -1.0
Date: 2019-12-31
Eps Actual: -0.2
Date: 2018-12-31
Eps Actual: 2.0
Date: 2015-12-31
Eps Actual: -0.2